MA31999B1 - Proteines de liaison a l'antigene - Google Patents

Proteines de liaison a l'antigene

Info

Publication number
MA31999B1
MA31999B1 MA32987A MA32987A MA31999B1 MA 31999 B1 MA31999 B1 MA 31999B1 MA 32987 A MA32987 A MA 32987A MA 32987 A MA32987 A MA 32987A MA 31999 B1 MA31999 B1 MA 31999B1
Authority
MA
Morocco
Prior art keywords
amyloid
antigen
binding proteins
diseases
methods
Prior art date
Application number
MA32987A
Other languages
Arabic (ar)
English (en)
Inventor
Philippe Marc Louis Alard
Jonathan Henry Ellis
Susannah Karen Ford
Volker Germaschewski
Alan Peter Lewis
Peter Ernest Soden
Pamela Joan Thomas
Trevor Anthony Kenneth Wattam
Ian Richard Catchpole
Gerald Wayne Gough
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40547800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31999(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0724185A external-priority patent/GB0724185D0/en
Priority claimed from GB0806230A external-priority patent/GB0806230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA31999B1 publication Critical patent/MA31999B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des protéines de liaison à l'antigène qui se lient au peptide ²-amyloïde, en particulier au peptide ²-amyloïde humain; des méthodes utilisant ces protéines de liaison à l'antigène pour traiter des maladies ou des troubles caractérisés par des taux élevés de ²-amyloïde ou des dépôts ²-amyloïdes, notamment la maladie d'alzheimer et des maladies ou des troubles affectant l'sil ou le nerf optique et qui sont caractérisés par des taux élevés de ²-amyloïde ou des dépôts ²-amyloïdes, y compris la dégénérescence maculaire liée à l'âge et des maladies du type glaucome et la formation de cataracte dépendant des protéines ²-amyloïdes; des compositions pharmaceutiques comprenant ces protéines de liaison à l'antigène; et des procédés de fabrication.
MA32987A 2007-12-11 2010-07-05 Proteines de liaison a l'antigene MA31999B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0724185A GB0724185D0 (en) 2007-12-11 2007-12-11 Antibodies
GB0806230A GB0806230D0 (en) 2008-04-04 2008-04-04 Antibodies
US4383908P 2008-04-10 2008-04-10
PCT/EP2008/067138 WO2009074583A1 (fr) 2007-12-11 2008-12-09 Protéines de liaison à l'antigène

Publications (1)

Publication Number Publication Date
MA31999B1 true MA31999B1 (fr) 2011-01-03

Family

ID=40547800

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32987A MA31999B1 (fr) 2007-12-11 2010-07-05 Proteines de liaison a l'antigene

Country Status (24)

Country Link
US (2) US20110014182A1 (fr)
EP (1) EP2222705B1 (fr)
JP (2) JP5512537B2 (fr)
KR (2) KR101657637B1 (fr)
CN (1) CN101970484B (fr)
AR (1) AR069610A1 (fr)
AU (1) AU2008334637B2 (fr)
BR (1) BRPI0819916A2 (fr)
CA (1) CA2707859A1 (fr)
CL (1) CL2008003655A1 (fr)
CO (1) CO6280540A2 (fr)
CR (1) CR11561A (fr)
DO (1) DOP2010000170A (fr)
EA (1) EA022913B1 (fr)
ES (1) ES2525704T3 (fr)
IL (1) IL206188A0 (fr)
MA (1) MA31999B1 (fr)
MX (1) MX2010006422A (fr)
NZ (1) NZ586003A (fr)
PE (1) PE20091449A1 (fr)
TW (1) TWI388334B (fr)
UY (1) UY31520A1 (fr)
WO (1) WO2009074583A1 (fr)
ZA (1) ZA201004133B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2586795B1 (fr) 2007-10-05 2018-05-16 Genentech, Inc. Utilisation d'anticorps anti-beta amyloide aux maladies oculaires
CA2791278C (fr) 2010-02-25 2015-11-24 The Johns Hopkins University Delivrance prolongee d'agents therapeutiques a un compartiment oculaire
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CA2832106A1 (fr) * 2011-04-07 2012-10-11 Neotope Biosciences Limited Compositions et procedes pour traiter des maladies d'agregation de proteines impliquant un depot d'ic3b
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
US10112988B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
CA2862999A1 (fr) * 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Fragments d'anticorps bispecifiques pour proteines associees a une maladie neurologique, et procedes d'utilisation
WO2015006507A1 (fr) 2013-07-09 2015-01-15 Annexon, Inc. Méthodes permettant de traiter la maladie d'alzheimer et la maladie de huntington
AU2014339900B2 (en) * 2013-10-25 2019-10-24 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
DK3105250T3 (da) * 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
ES3013108T3 (en) * 2014-11-05 2025-04-11 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
EP3340983B1 (fr) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Composés aryle, hétéroaryle, et hétérocycliques pour le traitement de troubles immunitaires et inflammatoires
WO2017035405A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amino pour le traitement de troubles immunitaires et inflammatoires
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035401A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amide pour le traitement de troubles immunitaires et inflammatoires
CN115260310B (zh) 2015-11-24 2025-02-25 安尼艾克松股份有限公司 抗补体因子c1q的fab片段及其应用
EP3405577B8 (fr) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions et procédés pour inhiber le facteur d
CN105542005B (zh) * 2016-02-03 2018-11-09 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
EP3529618B1 (fr) * 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. Procédé de quantification de c5 non liée dans un échantillon
ES2888904T3 (es) * 2016-10-19 2022-01-10 Alexion Pharma Inc Un método de cuantificación de C5a sin unir en una muestra
WO2018136827A1 (fr) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Compositions à boucle en épingle à cheveux et procédés pour inhiber le facteur d
WO2018160891A1 (fr) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Composés pharmaceutiques destinés au traitement de troubles médicaux
US20200330592A1 (en) * 2017-10-09 2020-10-22 Keith Black Compositions and methods of treating alzheimer's and other amyloid related diseases
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
BR112021011727A2 (pt) 2018-12-17 2021-08-31 Achillion Pharmaceuticals, Inc Dosagem direcionada para o tratamento de distúrbios mediados do complemento
WO2020198062A1 (fr) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Composés pharmaceutiques pour le traitement de troubles médiés par le complément
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
US20230126447A1 (en) * 2020-03-10 2023-04-27 Achillion Pharmaceuticals, Inc. Ocular drug depot for complement-mediated disorders
JP2021141861A (ja) * 2020-03-13 2021-09-24 富士フイルム和光純薬株式会社 抗原に対する親和力が向上した抗体のスクリーニング方法および製造方法
CN113929748B (zh) * 2020-07-13 2023-10-20 中国科学技术大学 检测bace1酶活性的试剂盒及用途
WO2023114763A1 (fr) 2021-12-13 2023-06-22 Annexon, Inc. Anticorps anti-facteur du complément c1q à bras de liaison uniques et leurs utilisations
AU2024231685A1 (en) * 2023-03-03 2025-09-25 Case Western Reserve University Cell adhesion molecule targeted immunotherapies
CN117131608B (zh) * 2023-10-23 2024-03-15 南京航空航天大学 一种基于最佳环量分布的激励盘方法
CN118258998B (zh) * 2024-05-31 2024-08-09 北京大学人民医院 一种抗原特异性b细胞检测探针及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0683234B2 (fr) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
AU5286999A (en) * 1999-07-23 2001-02-13 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent
ES2392247T3 (es) 2002-03-05 2012-12-07 Ramot At Tel-Aviv University Ltd. Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide
EP1633786A4 (fr) * 2002-10-09 2007-07-25 Rinat Neuroscience Corp Methodes de traitement de la maladie d'alzheimer au moyen d'anticorps diriges contre le peptide g(b)-amyloide et compositions les comprenant
US7575747B2 (en) 2003-02-10 2009-08-18 Applied Molecular Evolution Aβ binding molecules
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
DK2177536T3 (da) * 2006-03-30 2014-07-14 Glaxo Group Ltd Antistoffer mod amyloid-beta-peptid
US20090022728A1 (en) 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases

Also Published As

Publication number Publication date
EP2222705B1 (fr) 2014-10-22
EA022913B1 (ru) 2016-03-31
US20090162358A1 (en) 2009-06-25
BRPI0819916A2 (pt) 2015-05-19
TW200932267A (en) 2009-08-01
KR20100099277A (ko) 2010-09-10
KR101629365B1 (ko) 2016-06-14
CR11561A (es) 2010-09-23
CA2707859A1 (fr) 2009-06-18
CN101970484B (zh) 2014-10-01
JP2014177462A (ja) 2014-09-25
NZ586003A (en) 2012-08-31
ZA201004133B (en) 2011-11-30
PE20091449A1 (es) 2009-10-07
KR20150100964A (ko) 2015-09-02
CO6280540A2 (es) 2011-05-20
ES2525704T3 (es) 2014-12-29
US8921523B2 (en) 2014-12-30
AU2008334637B2 (en) 2014-08-07
TWI388334B (zh) 2013-03-11
EP2222705A1 (fr) 2010-09-01
JP5512537B2 (ja) 2014-06-04
AR069610A1 (es) 2010-02-03
EA201000787A1 (ru) 2010-12-30
AU2008334637A1 (en) 2009-06-18
MX2010006422A (es) 2010-06-25
DOP2010000170A (es) 2010-08-15
UY31520A1 (es) 2009-08-03
IL206188A0 (en) 2010-12-30
KR101657637B1 (ko) 2016-09-19
US20110014182A1 (en) 2011-01-20
WO2009074583A1 (fr) 2009-06-18
JP2011506387A (ja) 2011-03-03
CN101970484A (zh) 2011-02-09
CL2008003655A1 (es) 2010-04-16

Similar Documents

Publication Publication Date Title
EA201000787A1 (ru) Антигенсвязывающие белки
MA30337B1 (fr) Anticorps
PH12011502389A1 (en) Monoclonal antibody
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
EA201100654A1 (ru) Соединения для лечения офтальмологических заболеваний и расстройств
PH12015501208A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
JP2017105786A (ja) 低親和性血液脳関門受容体抗体及びその使用
MA67288A1 (fr) Tubulysines et conjugués tubulysines-protéines
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
WO2006091796A3 (fr) Compositions et methodes destinees au diagnostic et au traitement de maladies retiniennes
EP2213684A3 (fr) Anticorps nogo-a pour le traitement de la maladie d'Alzheimer
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA47392A1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA58646A1 (fr) Tubulysines et conjugués tubulysines-protéines
TW202035442A (zh) 經修飾之抗體Fc及其使用方法
EA201100462A1 (ru) Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств
US20130149237A1 (en) Delivery system for diagnostic and therapeutic agents
DE602004010314D1 (de) Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren
MA48241A1 (fr) Anticorps dirigés contre madcam
WO2006110367A3 (fr) Procedes et compositions pour toxines mycoplasma
MA35580B1 (fr) Composition pharmaceutique
CY1115021T1 (el) Μονοκλωνικα αντισωματα εναντι αμυλοειδους βητα πρωτεϊνης και χρησεις αυτων